XML 27 R3.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statements of Loss on Comprehensive Loss - USD ($)
$ in Thousands
 10 Months Ended 12 Months Ended
Dec. 31, 2019
Dec. 31, 2021
Dec. 31, 2020
Consolidated Statements of Loss on Comprehensive Loss      
Revenue (note 25) $ 0 $ 8,980 $ 106
Cost Of Sales 0 6,627 35
Gross Profit Before Gain On Fair Value Of Biological Assets 0 2,353 71
Unrealized Gain On Changes In Fair Value Of Biological Assets (note 7) 0 72 0
Gross Profit 0 2,425 71
Operating Expenses      
Consulting And Management Fees 2,001 7,324 4,752
Professional Fees 183 4,269 794
General And Administrative 175 4,507 1,400
Travel Expenses 306 603 428
Share Based Compensation (note 17) 107 1,340 4,901
Research And Development 21 132 78
Depreciation And Amortization (notes 9 And 12) 26 765 113
Bad Debt Expense (note 5) 0 1,335 0
Goodwill Impairment (notes 12 And 13) 0 51 1,816
Other Expenses (income), Net 0 1,050 73
Total Operating Expenses 2,819 21,376 14,355
Operating Loss (2,819) (18,951) (14,284)
Interest Expense 19 84 30
Foreign Exchange Loss 6 79 20
Unrealized Loss On Fair Value Of Investments (note 10) 0 2,345 0
Net Loss Before Income Taxes (2,844) (21,459) (14,334)
Income Tax Benefit (note 21) 0 98 0
Net Loss For The Period (2,844) (21,361) (14,334)
Other Comprehensive Loss      
Exchange Differences On Foreign Operations 23 (1,147) 16
Total Comprehensive Loss For The Period (2,821) (22,508) (14,318)
Net Loss Attributable To:      
Flora Growth Corp. (2,824) (21,249) (14,170)
Non-controlling Interests (20) (112) (164)
Comprehensive Loss Attributable To:      
Flora Growth Corp. $ (2,801) $ (22,396) $ (14,154)
Basic And Diluted Loss Per Share Attributable To Flora Growth Corp. $ 0.19 $ (0.48) $ (0.47)
Weighted Average Number Of Common Shares Outstanding - Basic And Diluted (note 22) 14,892 43,954 29,901